Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Associations of percent density with ER-positive and ER-negative breast cancer, by BMI and menopausal status for 1823 cases and 4720 controls

From: Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype

  Normal/underweight
BMI < 25 kg/m2
Overweight/obese
BMI ≥ 25 kg/m2
  Cases Controls Percent density
OR per S.D. (95% CI)a
P het b Cases Controls Percent density
OR per S.D. (95% CI)a
P het b
Premenopausalc     0.27     0.01
 ER-positive cancer 325 979 1.90 (1.57–2.29)   180 528 1.33 (1.11–1.61)  
 ER-negative cancer 58 979 1.51 (1.04–2.21)   47 528 2.17 (1.50–3.16)  
Postmenopausal HT userd     0.22     0.89
 ER-positive cancer 240 678 1.71 (1.42–2.05)   171 446 1.60 (1.30–1.96)  
 ER-negative cancer 41 678 1.34 (0.92–1.94)   27 446 1.66 (1.06–2.60)  
Postmenopausal HT non-usere     0.25     0.66
 ER-positive cancer 228 1029 1.51 (1.27–1.80)   394 1060 1.50 (1.31–1.71)  
 ER-negative cancer 51 1029 1.23 (0.89–1.70)   61 1060 1.40 (1.04–1.87)  
  1. Abbreviations: BMI body mass index, CI confidence interval, ER estrogen receptor, HT hormone therapy, OR odds ratio, S.D. standard deviation
  2. aOdds ratios estimated from polytomous multivariable logistic regression models adjusted for age, study. Standard deviation of square root-transformed percent density = 2.0
  3. bP value of heterogeneity of association between percent density and ER subtypes within BMI groups
  4. cPint = 0.008 for BMI-percent density interaction within premenopausal women
  5. dPint = 0.58 for BMI-percent density interaction within postmenopausal HT users
  6. ePint = 0.89 for BMI-percent density interaction within postmenopausal HT non-users